Results 101 to 110 of about 11,211 (144)

Effect of dolutegravir on 'Life's Simple 7' cardiovascular risk factors: A longitudinal analysis from Tanzania. [PDF]

HIV Med
Manyangu GJ, Wajanga B, Desderius B, Fadhili S, Willkens M, Myalla C, Kisigo GA, Praygod G, Lee MH, Peck RN, Kalluvya S, Yan LD.   +11 more
europepmc   +1 more source

'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort. [PDF]

J Antimicrob Chemother
Ciccullo A, Baldin G, Cervo A, Oreni L, Mazzitelli M, Gasparro G, Menozzi M, Cesaretti M, Bassani F, Lagi F, Lombardi F, Giacomelli A, Borghetti A, Fabbiani M, Rusconi S, Cattelan A, Antinori S, Mussini C, Di Giambenedetto S.   +18 more
europepmc   +1 more source

Effect of transitioning virally suppressed children and adolescents with HIV to dolutegravir-based antiretroviral therapy: emulated target trials in a large cohort in South Africa

Brown JA, Sookrajh Y, Mtila L, Lushaba N, Hlabisa M, van der Molen JS, Tlhaku K, Nkosi M, Ngwenya T, Khubone T, Mahomed S, Chammartin F, Archary M, Garrett N, Lewis L, Dorward J.   +15 more
europepmc   +1 more source

Quantum dot (QD)-based silicon as an efficient catalyst for the one-pot synthesis of polynuclear acridines: molecular docking investigation of putative anti-tubercular and anti-HIV drug candidates. [PDF]

RSC Adv
Tarek M, Said GE, Al-Omar MA, Almehizia AA, Naglah AM, Alshammari A, Ghabbour HA, Khatab TK.   +7 more
europepmc   +1 more source

Virtual screening and cellular validation of dolutegravir as a BRD9 inhibitor for attenuating pyroptosis in peritoneal mesothelial cells. [PDF]

Ren Fail
Gai J, Xing X, Gong C, Teng Y, Chen S, Yang M, Lou W.   +6 more
europepmc   +1 more source

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model. [PDF]

Braz J Med Biol Res
Chege BM, Mwangi PW, Githinji CG, Bukachi F.   +3 more
europepmc   +1 more source

Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial. [PDF]

Clin Infect Dis
Brites C, Montaño-Castellon I, Arriaga MB, Marconi C, Mayoral R, Luz E, Figueredo CA, Fiuza BSD, Netto EM.   +8 more
europepmc   +1 more source

Brief Report: Association Between Pharmacologic Tenofovir Adherence Measures and Subsequent 24-Week Viral Load Outcomes for People With HIV in South Africa. [PDF]

J Acquir Immune Defic Syndr
Bodley N, Govender K, Moodley P, Samsunder N, Sookrajh Y, Turner PJ, Butler CC, Hayward GN, Gandhi M, Drain PK, Garrett N, Dorward J.   +11 more
europepmc   +1 more source

Kidney abnormalities in young people living with HIV on dolutegravir-based regimens in Kampala, Uganda. [PDF]

AIDS Res Ther
Nasuuna EM, Hoffman R, Kalyesubula R, Chikwari CD, Weiss HA.   +4 more
europepmc   +1 more source